The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies (Abs) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) Abs, are effective for patients with various cancers. However, low response rates to ...

Source: Molecular Cancer - May 2, 2020 Category: Cancer & Oncology Authors: Xueping Wang, Fang Wang, Mengjun Zhong, Yosef Yarden and Liwu Fu Tags: Review Source Type: research